Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Feb 9, 2015 at 9:50 AM EST

Achillion Breaks Through Phase 2 HCV

Achillion Pharmaceuticals has announced updated interim results from an ongoing Phase 2 study and the stock saw a solid boost…

Chris Lange | Feb 6, 2015 at 12:15 PM EST

Credit Suisse Gives Up on Gilead, Sort Of

Credit Suisse downgraded Gilead Sciences to Neutral and lowered its price target, citing increased competition for hepatitis C drugs.

Lee Jackson | Feb 6, 2015 at 10:10 AM EST

5 Top Credit Suisse Health Care Stock Picks to Buy for 2015

24/7 Wall St. reviewed the new Credit Suisse Top Picks for 2015 report, and here are five of the top…

Chris Lange | Feb 5, 2015 at 2:10 PM EST

More Proof of Accelerating Boston Scientific Turnaround

Boston Scientific is pushing forward in its long turnaround and is gathering more speed.

Chris Lange | Feb 5, 2015 at 10:10 AM EST

Are Teva’s Earnings Good Enough?

Prior to the markets opening Thursday, Teva Pharmaceutical reported its most recent financial results.

Lee Jackson | Feb 5, 2015 at 10:00 AM EST

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the…

Paul Ausick | Feb 4, 2015 at 11:10 AM EST

Just How Bad Have Things Gotten at Myriad Genetics?

Myriad Genetics shares traded down as much as 16% Wednesday morning after the company lowered its fiscal-year guidance.

Jon C. Ogg | Feb 4, 2015 at 10:45 AM EST

Gilead Dividend and Buyback Different From Amgen’s Strategy

Gilead Sciences has become so large and accumulated enough capital that it has decided to begin paying a dividend, a…

Chris Lange | Feb 4, 2015 at 9:40 AM EST

Loss of Hep C Drug Status Weighs on Merck Earnings

Merck reported largely in-line fourth-quarter financial results Wednesday before the U.S. markets opened.

Chris Lange | Feb 3, 2015 at 4:58 PM EST

Will Increased Competition Hurt Gilead’s Outlook?

Gilead Sciences reported better-than-expected fourth-quarter results Tuesday after the markets closed.

Chris Lange | Feb 3, 2015 at 12:20 PM EST

What to Expect From Gilead Earnings

Tuesday after the U.S. markets close, Gilead Sciences will report its fourth-quarter financial results.

Lee Jackson | Feb 3, 2015 at 9:25 AM EST

Portfolio Managers Love These 5 Biotech Stocks

Here are the five biotech stocks that are loved the most by portfolio managers, according to Cowen analysts.

Chris Lange | Jan 30, 2015 at 10:35 AM EST

Did Biogen Run Too Much After Earnings?

Biogen Idec shares hit a new multiyear high Friday morning following the better-than-expected fourth-quarter earnings.

Chris Lange | Jan 30, 2015 at 8:55 AM EST

Are Humira Sales Enough to Lift AbbVie?

AbbVie reported better-than-expected fourth-quarter financial results Friday before the markets open.

Chris Lange | Jan 29, 2015 at 10:45 AM EST

Is Celgene’s Outlook Good Enough for Investors?

Celgene Corp. (NASDAQ: CELG) reported better-than-expected fourth-quarter earnings on Thursday morning.

1 … 270 271 272 273 274 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Achillion Breaks Through Phase 2 HCV

Credit Suisse Gives Up on Gilead, Sort Of

5 Top Credit Suisse Health Care Stock Picks to Buy for 2015

More Proof of Accelerating Boston Scientific Turnaround

Are Teva’s Earnings Good Enough?

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

Just How Bad Have Things Gotten at Myriad Genetics?

Gilead Dividend and Buyback Different From Amgen’s Strategy

Loss of Hep C Drug Status Weighs on Merck Earnings

Will Increased Competition Hurt Gilead’s Outlook?

What to Expect From Gilead Earnings

Portfolio Managers Love These 5 Biotech Stocks

Did Biogen Run Too Much After Earnings?

Are Humira Sales Enough to Lift AbbVie?

Is Celgene’s Outlook Good Enough for Investors?

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Live: Will Palantir Beat Q1 Earnings Tonight After Market Close?

How Nvidia’s Jensen Huang Used The Innovator’s Dilemma to Dominate

Meta Platforms vs Snap: Who’s Really Winning Digital Ads?

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

How Nvidia’s Jensen Huang Used The Innovator’s Dilemma to Dominate

Live: onsemi Q1 Earnings Tonight. Can the Stock Continue Its 90% YTD Rally?

Health and Healthcare Articles

All Health and Healthcare Articles

Achillion Breaks Through Phase 2 HCV

Credit Suisse Gives Up on Gilead, Sort Of

5 Top Credit Suisse Health Care Stock Picks to Buy for 2015

More Proof of Accelerating Boston Scientific Turnaround

Are Teva’s Earnings Good Enough?

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

Just How Bad Have Things Gotten at Myriad Genetics?

Gilead Dividend and Buyback Different From Amgen’s Strategy

Loss of Hep C Drug Status Weighs on Merck Earnings

Will Increased Competition Hurt Gilead’s Outlook?

What to Expect From Gilead Earnings

Portfolio Managers Love These 5 Biotech Stocks

Did Biogen Run Too Much After Earnings?

Are Humira Sales Enough to Lift AbbVie?

Is Celgene’s Outlook Good Enough for Investors?

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Live: Will Palantir Beat Q1 Earnings Tonight After Market Close?

How Nvidia’s Jensen Huang Used The Innovator’s Dilemma to Dominate

Meta Platforms vs Snap: Who’s Really Winning Digital Ads?

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how